Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
McKinsey
Baxter
Dow
Mallinckrodt

Last Updated: January 27, 2023

CLINICAL TRIALS PROFILE FOR RELISTOR


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Relistor

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00672139 ↗ Safety of Subcutaneous Methylnaltrexone for Opioid-Induced Constipation in Patients With Advanced Illness Completed Progenics Pharmaceuticals, Inc. Phase 4 2008-07-01 This is an open-label, multicenter extension of study 3200K1-4000-WW that will evaluate the safety of methylnaltrexone. This drug will be administered by subcutaneous injection and will be tested in late stage, advanced illness patients who have constipation caused by opioid pain relievers. This study will last 3 months.
NCT00672139 ↗ Safety of Subcutaneous Methylnaltrexone for Opioid-Induced Constipation in Patients With Advanced Illness Completed Bausch Health Americas, Inc. Phase 4 2008-07-01 This is an open-label, multicenter extension of study 3200K1-4000-WW that will evaluate the safety of methylnaltrexone. This drug will be administered by subcutaneous injection and will be tested in late stage, advanced illness patients who have constipation caused by opioid pain relievers. This study will last 3 months.
NCT00672139 ↗ Safety of Subcutaneous Methylnaltrexone for Opioid-Induced Constipation in Patients With Advanced Illness Completed Valeant Pharmaceuticals International, Inc. Phase 4 2008-07-01 This is an open-label, multicenter extension of study 3200K1-4000-WW that will evaluate the safety of methylnaltrexone. This drug will be administered by subcutaneous injection and will be tested in late stage, advanced illness patients who have constipation caused by opioid pain relievers. This study will last 3 months.
NCT00672477 ↗ Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With Advanced Illness Completed Progenics Pharmaceuticals, Inc. Phase 4 2008-06-01 This study will evaluate the safety and efficacy of methylnaltrexone administered as subcutaneous injections in subjects who have opioid-induced constipation and an advanced illness. The hypothesis is that methylnaltrexone will be safe and effective in relieving opioid-induced constipation in these subjects.
NCT00672477 ↗ Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With Advanced Illness Completed Bausch Health Americas, Inc. Phase 4 2008-06-01 This study will evaluate the safety and efficacy of methylnaltrexone administered as subcutaneous injections in subjects who have opioid-induced constipation and an advanced illness. The hypothesis is that methylnaltrexone will be safe and effective in relieving opioid-induced constipation in these subjects.
NCT00672477 ↗ Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With Advanced Illness Completed Valeant Pharmaceuticals International, Inc. Phase 4 2008-06-01 This study will evaluate the safety and efficacy of methylnaltrexone administered as subcutaneous injections in subjects who have opioid-induced constipation and an advanced illness. The hypothesis is that methylnaltrexone will be safe and effective in relieving opioid-induced constipation in these subjects.
NCT00804141 ↗ Study Evaluating Long-Term Safety of MOA-728 in Participants With Opioid-Induced Constipation Completed Pfizer Phase 3 2008-12-03 This study is designed to evaluate the long-term safety and tolerability of the subcutaneous (SC) injection form of N-methylnaltrexone bromide (MOA-728) for the treatment of opioid-induced constipation in participants with nonmalignant pain. The study consists of a 2-week screening period, a 48-week open-label treatment period and a 2 week follow-up period. Participants will need to agree to self-administer SC injections, complete daily diaries, and check-in via a daily telephone call during the study.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Relistor

Condition Name

Condition Name for Relistor
Intervention Trials
Opioid-Induced Constipation 4
Constipation 4
Pharyngeal Dysfunction 2
Acute Pancreatitis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Relistor
Intervention Trials
Constipation 10
Opioid-Induced Constipation 7
Critical Illness 1
Myocardial Ischemia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Relistor

Trials by Country

Trials by Country for Relistor
Location Trials
United States 65
Canada 17
Australia 5
Spain 3
Korea, Republic of 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Relistor
Location Trials
Pennsylvania 4
Florida 4
North Carolina 4
Utah 3
Texas 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Relistor

Clinical Trial Phase

Clinical Trial Phase for Relistor
Clinical Trial Phase Trials
Phase 4 10
Phase 3 4
Phase 2/Phase 3 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Relistor
Clinical Trial Phase Trials
Completed 10
Recruiting 2
Unknown status 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Relistor

Sponsor Name

Sponsor Name for Relistor
Sponsor Trials
Bausch Health Americas, Inc. 4
Valeant Pharmaceuticals International, Inc. 4
Wyeth is now a wholly owned subsidiary of Pfizer 4
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Relistor
Sponsor Trials
Other 17
Industry 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
Baxter
Moodys
Express Scripts
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.